20/20 Biolabs, Inc.
AIDX
$1.46
$0.096.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 32.65% | 34.78% | 7.45% | 8.40% | 13.14% |
| Total Depreciation and Amortization | -38.05% | -31.07% | -22.37% | -15.85% | -17.21% |
| Total Amortization of Deferred Charges | 2,202.00% | 173.02% | -100.00% | -60.94% | -3.85% |
| Total Other Non-Cash Items | -64.31% | -38.69% | 79.12% | 130.56% | 44.71% |
| Change in Net Operating Assets | 35.05% | -18.00% | 57.41% | 27.22% | 174.40% |
| Cash from Operations | 26.13% | 36.96% | 39.25% | 41.98% | 41.99% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -34.40% | 64.98% | 268.82% | 551.93% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 296.11% | 468.20% | 874.35% | 393.00% | 250.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 67.12% | 63.77% | 51.73% | 51.91% | 51.13% |